For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 11,707 | 11,468* | 11,915 | 12,613 |
| General and administrative | 3,908 | 3,745* | 3,586 | 3,711 |
| Total operating expenses | 15,615 | 15,212 | 15,501 | 16,324 |
| Loss from operations | -15,615 | -15,212* | -15,501 | -16,324 |
| Interest income | 458 | 831* | 804 | 934 |
| Interest and other expense | - | 2* | 2 | - |
| Total other income | 458 | 829* | 802 | 934 |
| Net loss and comprehensive loss | -15,157 | -14,383 | -14,699 | -15,390 |
| Basic EPS | -1.11 | -1.065 | -1.09 | -1.14 |
| Diluted EPS | -1.11 | -1.065 | -1.09 | -1.14 |
| Basic Average Shares | 13,674,577 | 13,507,773 | 13,530,892 | 13,509,080 |
| Diluted Average Shares | 13,674,577 | 13,507,773 | 13,530,892 | 13,509,080 |
OnKure Therapeutics, Inc. (OKUR)
OnKure Therapeutics, Inc. (OKUR)